Aytu Biopharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Aytu Biopharma Inc AYTU.O is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2026
The Denver Colorado-based company is expected to report a 4.4% decrease in revenue to $13.271 million from $13.89 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Aytu Biopharma Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aytu Biopharma Inc is $7.00, about 282.5% above its last closing price of $1.83
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -0.32 | 0.00 | Beat | 99.7 | |
Mar. 31 2026 | -0.46 | -0.51 | -0.53 | Missed | -3.9 |
Dec. 31 2025 | -0.60 | -0.60 | -1.05 | Missed | -75 |
Sep. 30 2025 | -0.23 | -0.23 | 0.21 | Beat | 191.3 |
Jun. 30 2025 | -0.04 | -0.04 | -2.92 | Missed | -7,862.9 |
Mar. 31 2025 | -0.17 | -0.17 | 0.21 | Beat | 223.5 |
Dec. 31 2024 | -0.28 | -0.28 | -0.26 | Beat | 7.1 |
Sep. 30 2024 | -0.34 | -0.34 | 0.44 | Beat | 229.4 |
This summary was machine generated November 9 at 21:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)